← Issue №18/ week of Nov 1, 2026/Hepatology

Excess Liver Fat in Type 2 Diabetes Stratified by Intrapancreatic Fat Deposition: A Meta-Analysis of Dual-Organ MRI Studies.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology meta analysis · n=2,142 · Nov 1, 2026 · Liver International · IF 6.7

Excess Liver Fat in Type 2 Diabetes Stratified by Intrapancreatic Fat Deposition: A Meta-Analysis of Dual-Organ MRI Studies.

New evidenceMASLDmeta-analysisbiomarkerepidemiology
Clinical takeawayNo clinical action yet: this meta-analysis identifies an association between IPFD and LFC in T2DM at the study level, but individual-level analyses are needed to clarify clinical implications.
What it foundIndividuals with T2DM had significantly higher liver fat content (LFC) than non-diabetic controls (SMD 0.89, 95% CI 0.60-1.18), with larger excess in studies with mean intrapancreatic fat deposition (IPFD) ≥ 10% (SMD 1.20 vs. 0.62; p = 0.04).
ContextThis meta-analysis confirms that T2DM is associated with higher LFC and suggests a potential link with IPFD, refining prior evidence on metabolic fat distribution in T2DM.
Emergingsuggested applicable standard· American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Manage diabetes in GI/hepatology patients by individualizing the A1c target to the population, in cirrhosis, A1c is unreliable because altered red blood cell turnover typically underestimates glycemia, so set glycemic goals using blood glucose monitoring and/or CGM rather than a fixed A1c cutoff, and in diabetic gastroparesis individualize the target rather than applying a universal cutoff; ≤7% pre-bariatric, <6.5% pre-conception, while screening all T2DM for MASLD with FIB-4, screening T1DM for concurrent celiac disease, and screening for diabetic gastroparesis when chronic nausea, early satiety, or postprandial fullness are present. Evaluate new-onset DM after age 50 without obesity for a pancreatic cancer differential, and coordinate peri-procedural medication holds and multidisciplinary endocrinology involvement.

American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149 · reviewed 2026-07-23 ↗
Sul HH … Petrov MS · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues